J&J Files NDA For Once-Monthly Dose Of Invega
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is seeking approval of long-acting injectable paliperidone in schizophrenia.
You may also be interested in...
J&J Pipeline On Track; Tapentadol Filing Expected This Week
Firm reports fourth quarter pharmaceutical sales of $6.4 billion worldwide and $3.9 billion in the U.S.
J&J Pipeline On Track; Tapentadol Filing Expected This Week
Firm reports fourth quarter pharmaceutical sales of $6.4 billion worldwide and $3.9 billion in the U.S.
Better Results For Invega Over Seroquel Could Enhance J&J’s Bottom Line At AstraZeneca’s Expense
Invega could cut into Seroquel’s hefty share of “churn” segment of antipsychotic market.